Ten Capital Wealth Advisors’s Biogen BIIB Stock Holding History

Ten Capital Wealth Advisors’s Portfolio BIIB Stock Details BIIB Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2023 Q2	–	Sell	-43	Closed	-$12K	–	220
2023 Q1	$12K	Buy	+43	New	+$11.9K	﹤0.01%	356

Other funds holding BIIB

Primecap Management Pasadena, California $127B AUM 44.11% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return

JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return

T. Rowe Price Investment Management Baltimore, Maryland $145B AUM 22.78% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

ClearBridge Investments New York $115B AUM 24.78% 1-Year Est. Return

Ten Capital Wealth Advisors's BIIB Position: Q2 2023 in Review

Ten Capital Wealth Advisors sold out of Biogen (BIIB) in Q2 2023, closing a stake of 43 shares — an estimated $12K sold.

Ten Capital Wealth Advisors first reported a position in BIIB in Q1 2023 and held it in 1 quarter. The position peaked at $12K in Q1 2023. 1,008 funds tracked by Wall St. Rank hold BIIB as of Q2 2023.

Ten Capital Wealth Advisors reported no remaining Biogen position as of Q2 2023 after selling out during the quarter.
Ten Capital Wealth Advisors sold 43 Biogen shares in Q2 2023, an estimated $12K.
Ten Capital Wealth Advisors first reported a position in Biogen in Q1 2023 and held it in 1 quarter.
Ten Capital Wealth Advisors's Biogen position peaked at $12K in Q1 2023.
1,008 funds tracked by Wall St. Rank held Biogen as of Q2 2023.

Based on Ten Capital Wealth Advisors's 13F filing for Q2 2023, filed 31 Jul 2023.